For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How has the chronic pancreatitis (cp) grown historically, and what trends indicate future expansion?
The chronic pancreatitis (CP) market size has grown strongly in recent years. It will grow from $4.91 billion in 2024 to $5.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to the increasing prevalence of alcohol consumption, rising incidence of smoking, genetic predisposition and family history, growing awareness of pancreatic diseases, rising cases of diabetes linked to pancreatitis, increasing healthcare spending, improved access to healthcare services.
The chronic pancreatitis (CP) market size is expected to see strong growth in the next few years. It will grow to $6.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the rising geriatric population, increasing demand for enzyme replacement therapies, growing awareness of early diagnosis, expansion of healthcare infrastructure in emerging markets, development of novel pain management therapies, increasing research and clinical trials for pancreatitis treatment. Major trends in the forecast period include artificial intelligence in diagnostic imaging, minimally invasive surgical techniques, wearables for continuous health monitoring, next-generation sequencing for genetic testing, integration of machine learning in disease progression tracking, and the development of smart diagnostic tools.
Download Your Free Sample PDF:
Which key factors are driving the expansion of the chronic pancreatitis (cp) industry?
The increasing consumption of alcohol is expected to propel the growth of the chronic pancreatitis market going forward. Alcohol consumption refers to the intake of beverages containing ethanol, commonly for recreational, social, or cultural purposes, but it can also lead to dependency or health risks when consumed excessively. The increasing consumption of alcohol is driven by factors such as rising social acceptance, urbanization, changing lifestyles, and stress management practices, especially among younger populations. Alcohol consumption causes chronic pancreatitis by triggering inflammation and damage to pancreatic cells, leading to fibrosis, ductal blockages, and long-term dysfunction due to toxic metabolic byproducts. For instance, in December 2023, according to publication by Kirin Holdings Company Limited, a Japan-based beer and beverage holding company, the total global beer consumption in 2022 rose by about 5.4 million kiloliters (equivalent to around 8.5 billion 633ml bottles) compared to 2021, reaching approximately 192.1 million kiloliters. This increase of 2.9% was attributed to the easing of COVID-19's impact, amounting to roughly 303.5 billion 633ml bottles. Therefore, the increasing consumption of alcohol is driving the growth of the chronic pancreatitis market.
How is the chronic pancreatitis (cp) market segmented by product, application, and end-user?
The chronic pancreatitis (CP) market covered in this report is segmented –
1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments
2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Other End Users
Subsegments:
1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids
2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin
3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein
4) By Steroids: Prednisone, Dexamethasone
5) By Antibiotics: Ciprofloxacin, Metronidazole
6) By Other Treatments: Endoscopic Treatment, Surgery
View The Full Market Report:
What are the key trends shaping the chronic pancreatitis (cp) market in the forecast period?
Major companies operating in the chronic pancreatitis market are focusing on developing technological advancements such as enzyme replacement therapy to address exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. Enzyme replacement therapy involves taking oral pancreatic enzymes to aid digestion in patients with insufficient pancreatic function. For instance, in July 2023, First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, announced the results from the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme derived from the Yarrowia lipolytica yeast administered as an oral, non-systemic biologic capsule, designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.
Which leading companies are dominating the chronic pancreatitis (cp) market landscape?
Major companies operating in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy's Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech
Which geographic areas are expected to offer the highest growth opportunities in thechronic pancreatitis (cp) market?
North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Chronic Pancreatitis (CP) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Chronic Pancreatitis (CP) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment